, Tracking Stock Market Picks
Enter Symbol:
China Medical Technologies, Inc. (CMEDQ) [hlAlert]

down 86.70 %

China Medical Technologies, Inc. (CMED) rated Buy by Standpoint Research

Posted on: Friday,  Jul 17, 2009  8:25 AM ET by Standpoint Research

Standpoint Research rated Buy China Medical Technologies, Inc. (OTCBB: CMEDQ) on 07/17/2009, when the stock price was $19.25.
Since then, China Medical Technologies, Inc. has lost 86.70% as of 11/08/2012's recent price of $2.56.
If you would have followed this Standpoint Research's recommendation on CMEDQ, you would have lost 86.7% of your investment in 1210 days.

China Medical Technologies, Inc. (China Medical) is a People?s Republic of China-based medical device company, which develops, manufactures and markets advanced immunodiagnostic and molecular diagnostic products utilizing enhanced chemiluminescence immunoassay (ECLIA) technology, fluorescent in situ hybridization (FISH) technology and surface plasmon resonance (SPR) technology. The in-vitro diagnostics (IVD) products are used to detect and monitor various diseases and disorders through laboratory evaluation and analysis of blood, urine or other body fluids. The Company operates in two business segments: immunodiagnostic systems and molecular diagnostic systems. Immunodiagnostic systems include ECLIA analyzers and reagent kits. The molecular diagnostic systems include FISH imaging analyzers and probes. It also includes SPR systems and human papillomavirus- deoxyribonucleic acid (HPV-DNA) chips. The wholly owned subsidiary of the Company is CMED ECLIA Diagnostic Technology Ltd.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/17/2009 8:25 AM Buy
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy